A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Clinical trial NCT01047345 · COMPLETED

Trial details

NCT number: NCT01047345
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Cervical Cancers Vulvar Cancers Vaginal Cancers Genital Warts

Start date: 2010-02-24
Primary completion: 2011-06-10
Enrollment: 924

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.